display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
la/mBC - TNBC - L2 - all population
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC IMpassion-132, ITT population
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-119 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons